PulseJournal ClubResearchersJournalsExplore
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
May 31, 2026Open Access

Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAlejandro FalcónGCGregory M CoteJMJavier Molina‐Cerrillo

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates safety of lurbinectedin plus irinotecan in patients with advanced solid tumors, indicating manageable toxicity.

Key Points

  • The study aims to assess the safety profile of lurbinectedin combined with irinotecan in patients with advanced solid tumors.
  • Conducted a phase I/II trial (NCT02611024) with patients having advanced solid tumors.
  • Administered lurbinectedin at 2.0 mg/m2 and irinotecan at 75 mg/m2 on specific dosing schedules.
  • Analyzed adverse events and laboratory abnormalities graded using NCI-CTCAE v.4.
  • The most common treatment-related adverse events included fatigue (71%), diarrhea (62%), and nausea (59%).
  • Grade ≥ 3 adverse events were predominantly neutropenia (53%) and fatigue (14%).
  • Overall discontinuation rate due to treatment-related adverse events was 3% with one treatment-related death (0.4%).

Cite This Study

Falcón et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd0fa5783ba022b6fcb54https://doi.org/10.48620/98089
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors2026
  2. 2Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors2025 · 4 citations
  3. 3Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort2026
  4. 427O Lurbinectedin plus irinotecan in pre-treated gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)2024 · 1 citations
  5. 5Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in a phase 2 expansion cohort of patients (Pts) with synovial sarcoma (SS).2024 · 1 citations